Restatement of Previously Issued Financial Statements - Restatement of Consolidated Statement of Operations (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
REVENUES	$ 192,000	$ 0
COST AND EXPENSES
Research and Development	282,295	23,867
General and Administrative	1,430,553	599,234
Consulting and Professional Fees	587,470	246,214
Rent	58,071	0
Total Costs and Expenses	2,358,389	869,315
OPERATING LOSS	(2,166,389)	(869,315)
OTHER INCOME & (EXPENSES)
Interest Income	1,148	233
Interest Expense	(56,063)	(35,136)
Loss on Settlement of Debt through Equity Issuance beow Fair value	(942,015)	(1,112,230)
Loss on Settlement of Debt through issuance of Common Shares of Regen Biopharma, Inc. below fair value	(9,191,857)	0
Interest Expense attributable to amortization of discount	(150,806)	0
Expense Related to issuance of Convertible Debt to Star City	(247,500)	0
Preferred Shares of Regen Biopharma, Inc. pursuant to contractual obligations	(3,475)	$ 0
Other than Temporary Impairment Available for Sale Securities	(41,333,361)
Other Income	0	$ 490
Other Expense	0	(65,000)
Total Other Income & (Expense)	(51,923,929)	(1,211,643)
NET INCOME (LOSS)	(54,090,319)	(2,080,958)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	8,977,733	226,234
NET INCOME (LOSS) available to common shareholders	$ (45,112,586)	$ (1,854,724)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.016)	$ (0.001)
Weighted average number of shares outstanding	2,855,088,489	2,865,048,153
As Originally Reported
REVENUES	$ 192,000
COST AND EXPENSES
Research and Development	282,295
General and Administrative	1,430,553
Consulting and Professional Fees	587,470
Rent	58,071
Total Costs and Expenses	2,358,389
OPERATING LOSS	(2,166,389)
OTHER INCOME & (EXPENSES)
Interest Income	1,148
Interest Expense	(56,063)
Loss on Settlement of Debt through Equity Issuance beow Fair value	(942,015)
Loss on Settlement of Debt through issuance of Common Shares of Regen Biopharma, Inc. below fair value	(9,191,857)
Interest Expense attributable to amortization of discount	(150,806)
Expense Related to issuance of Convertible Debt to Star City	(247,500)
Preferred Shares of Regen Biopharma, Inc. pursuant to contractual obligations	$ (3,475)
Other than Temporary Impairment Available for Sale Securities
Other Income	$ 0
Other Expense	0
Total Other Income & (Expense)	(51,923,929)
NET INCOME (LOSS)	(12,756,958)	$ (2,080,958)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	8,977,733
NET INCOME (LOSS) available to common shareholders	$ (3,779,225)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.001)
Weighted average number of shares outstanding	2,855,088,489
Adjustments
OTHER INCOME & (EXPENSES)
Other than Temporary Impairment Available for Sale Securities	$ (41,333,361)
NET INCOME (LOSS)	(41,333,361)
NET INCOME (LOSS) available to common shareholders	$ (41,333,361)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.015)
Restated
REVENUES	$ 192,000
COST AND EXPENSES
Research and Development	282,295
General and Administrative	1,430,553
Consulting and Professional Fees	587,470
Rent	58,071
Total Costs and Expenses	2,358,389
OPERATING LOSS	(2,166,389)
OTHER INCOME & (EXPENSES)
Interest Income	1,148
Interest Expense	(56,063)
Loss on Settlement of Debt through Equity Issuance beow Fair value	(942,015)
Loss on Settlement of Debt through issuance of Common Shares of Regen Biopharma, Inc. below fair value	(9,191,857)
Interest Expense attributable to amortization of discount	(150,806)
Expense Related to issuance of Convertible Debt to Star City	(247,500)
Preferred Shares of Regen Biopharma, Inc. pursuant to contractual obligations	(3,475)
Other than Temporary Impairment Available for Sale Securities	(41,333,361)
Other Income	0
Other Expense	0
Total Other Income & (Expense)	(51,923,929)
NET INCOME (LOSS)	(54,090,319)	$ (2,080,958)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	8,977,733
NET INCOME (LOSS) available to common shareholders	$ (45,112,586)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.016)
Weighted average number of shares outstanding	2,855,088,489